Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, have signed a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao. This exclusive agreement broadens Helsinn’s existing partnerships for anamorelin in the area of cancer supportive care across multiple global territories. 

Helsin

mundipharma

ADVERTISEMENT

Under the terms of the new agreement, Helsinn retains all international development as well as regulatory and clinical development activities and the supply of anamorelin for commercial use. Mundipharma will obtain the rights to marketing, promotion, distribution and sales of anamorelin in the designated territories. 
Anamorelin is a novel, once-daily, orally active ghrelin receptor agonist under investigation for the treatment of Cancer Anorexia-Cachexia in patients suffering from non-small cell lung cancer (NSCLC), an area of significant unmet medical need. 

Riccardo Braglia, CEO of Helsinn Group, said: “This partnership is another step in what we foresee as a long and successful collaboration with Mundipharma. We believe that anamorelin could be established as an important advancement in the management of cancer anorexia-cachexia. Anamorelin offers the potential for a new approach of treating this multifactorial clinical condition which can be devastating for patients and caregivers. Anamorelin has been shown in two large-scale clinical studies to improve lean body mass, potentially enabling patients to tolerate more treatments, and to alleviate their symptoms and concerns, ultimately helping them get more out of every day.” 

Mr Raman Singh, President, Mundipharma Asia, Latin America, Middle East and Africa, said: “Improving the quality of patients’ lives has always been one of our core commitments, and the eventual launch of anamorelin in China seeks to provide healthcare professionals and patients with the effective support they need as patients undergo treatment. Our continued partnership with the Helsinn Group helps us further this goal, with their excellence in innovation and cancer supportive care.” 

Great news for both companies, the drug was also commented by the European Society for Medical Oncology (ESMO) in the “ESMO 2014 Wrap-Up: What should be remembered?” as one of the top innovations in oncology of 2014. 

Previous post

The Genomic Portrait of Iceland

Next post

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.